Construction of Yposkesi’s second commercial bioproduction site is underway
Project SKY features one of Europe’s largest facilities for advanced therapies, says CDMO
Yposkesi, a contract development and manufacturing organization (CDMO) that specializes in cell and gene therapies, has launched project SKY, the construction of Yposkesi’s second commercial cell and gene therapy facility; it is meant to be a resource for drug developers of biologics, also known as ATMPs (advanced therapy medicinal products). ATMPs treat patients living with rare and life-threatening diseases.
In March, Yposkesi welcomed SK Pharmteco, another CDMO, as a new majority equity shareholder in its company. Backed by SK Pharmteco, Yposkesi is investing approximately $71 million into the new 50,000 square-foot France site, making it one of the largest ATMP facilities in Europe, according to the company. Project SKY is expected to create 80 new jobs by 2023.
The new building will be home to two additional production lines with several 1000L scale bioreactors.
